The European Commission authorized BioNTech and Pfizer’s updated COVID-19 vaccine for the 2026-2027 season.
This marketing authorization covers individuals aged six months and older.
The approval applies to all 27 European Union member states.
The monovalent vaccine targets the XFG variant of the JN.1 lineage.
The vaccine design follows recommendations from the European Medicines Agency.
The companies have already begun manufacturing to ensure supply for the upcoming respiratory disease season.